Vantage logo

The lowdown on high blood pressure

After Idorsia’s tease in resistant hypertension, data will soon emerge on other advanced assets, including long-acting RNA-based approaches.

Vantage logo

The patent winter is coming

Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?